[1] |
Schmidt E, Zillikens D. Pemphigoid diseases[J]. Lancet, 2013,381(9863):320⁃332. doi: 10.1016/S0140⁃6736(12)61140⁃4.
|
[2] |
Daniel BS, Murrell DF. Review of autoimmune blistering diseases: the pemphigoid diseases[J]. J Eur Acad Dermatol Venereol, 2019,33(9):1685⁃1694. doi: 10.1111/jdv.15679.
|
[3] |
Bağcı IS, Horváth ON, Ruzicka T, et al. Bullous pemphigoid[J]. Autoimmun Rev, 2017,16(5):445⁃455. doi: 10.1016/j.autrev. 2017.03.010.
|
[4] |
Milani⁃Nejad N, Zhang M, Kaffenberger J. The association between bullous pemphigoid and neurological disorders: a systematic review[J]. Eur J Dermatol, 2017,27(5):472⁃481. doi: 10.1684/ejd.2017.3066.
|
[5] |
Teraki Y, Hotta T, Shiohara T. Skin⁃homing interleukin⁃4 and ⁃13⁃producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin⁃10⁃producing cells[J]. J Invest Dermatol, 2001,117(5):1097⁃1102. doi: 10.1046/j.0022⁃202x.2001.01505.x.
|
[6] |
Geller S. Interleukin 4 and interleukin 13 inhibition: a promising therapeutic approach in bullous pemphigoid[J]. J Am Acad Dermatol, 2020,83(1):37⁃38. doi: 10.1016/j.jaad.2020.03. 017.
|
[7] |
Hamilton JD, Suárez⁃Fariñas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate⁃to⁃severe atopic dermatitis[J]. J Allergy Clin Immunol, 2014,134(6):1293⁃1300. doi: 10.1016/j.jaci.2014.10.013.
|
[8] |
Russo R, Cozzani E, Gasparini G, et al. Targeting interleukin 4 receptor α: a new approach to the treatment of cutaneous autoimmune bullous diseases?[J]. Dermatol Ther, 2020,33(1):e13190. doi: 10.1111/dth.13190.
|
[9] |
Simpson EL, Bieber T, Guttman⁃Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis[J]. N Engl J Med, 2016,375(24):2335⁃2348. doi: 10.1056/NEJMoa1610020.
|
[10] |
Goletz S, Zillikens D, Schmidt E. Structural proteins of the dermal⁃epidermal junction targeted by autoantibodies in pemphigoid diseases[J]. Exp Dermatol, 2017,26(12):1154⁃1162. doi: 10.1111/exd.13446.
|
[11] |
Hammers CM, Stanley JR. Mechanisms of disease: pemphigus and bullous pemphigoid[J]. Annu Rev Pathol, 2016,11:175⁃197. doi: 10.1146/annurev⁃pathol⁃012615⁃044313.
|
[12] |
Iwata H, Kamio N, Aoyama Y, et al. IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180⁃kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment[J]. J Invest Dermatol, 2009,129(4):919⁃926. doi: 10.1038/jid.2008.305.
|
[13] |
Saniklidou AH, Tighe PJ, Fairclough LC, et al. IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review[J]. Arch Dermatol Res, 2018,310(1):11⁃28. doi: 10.1007/s00403⁃017⁃1789⁃1.
|
[14] |
Kalowska M, Ciepiela O, Kowalewski C, et al. Enzyme⁃linked immunoassay index for anti⁃NC16a IgG and IgE auto⁃antibodies correlates with severity and activity of bullous pemphigoid[J]. Acta Derm Venereol, 2016,96(2):191⁃196. doi: 10.2340/00015 555⁃2101.
|
[15] |
Cozzani E, Gasparini G, Di Zenzo G, et al. Immunoglobulin E and bullous pemphigoid[J]. Eur J Dermatol, 2018,28(4):440⁃448. doi: 10.1684/ejd.2018.3366.
|
[16] |
Messingham KN, Srikantha R, DeGueme AM, et al. FcR⁃independent effects of IgE and IgG autoantibodies in bullous pemphigoid[J]. J Immunol, 2011,187(1):553⁃560. doi: 10.4049/jimmunol.1001753.
|
[17] |
Giomi B, Caproni M, Calzolari A, et al. Th1, Th2 and Th3 cytokines in the pathogenesis of bullous pemphigoid[J]. J Dermatol Sci, 2002,30(2):116⁃128. doi: 10.1016/s0923⁃1811(02)00067⁃1.
|
[18] |
Simon D, Borradori L, Simon HU. Eosinophils as putative therapeutic targets in bullous pemphigoid[J]. Exp Dermatol, 2017,26(12):1187⁃1192. doi: 10.1111/exd.13416.
|
[19] |
Bushkell LL, Jordon RE. Bullous pemphigoid: a cause of peripheral blood eosinophilia[J]. J Am Acad Dermatol, 1983,8(5):648⁃651. doi: 10.1016/s0190⁃9622(83)70073⁃3.
|
[20] |
Wakugawa M, Nakamura K, Hino H, et al. Elevated levels of eotaxin and interleukin⁃5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia[J]. Br J Dermatol, 2000,143(1):112⁃116. doi: 10.1046/j.1365⁃2133.2000.03599.x.
|
[21] |
Hashimoto T, Kursewicz CD, Fayne RA, et al. Pathophysiologic mechanisms of itch in bullous pemphigoid[J]. J Am Acad Dermatol, 2020,83(1):53⁃62. doi: 10.1016/j.jaad.2019.07.060.
|
[22] |
中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会. 自身免疫性表皮下大疱病诊疗共识(2022)[J]. 中华皮肤科杂志, 2022,55(1):1⁃11. doi: 10.35541/cjd.20210532.
|
[23] |
Kaye A, Gordon SC, Deverapalli SC, et al. Dupilumab for the treatment of recalcitrant bullous pemphigoid[J]. JAMA Dermatol, 2018,154(10):1225⁃1226. doi: 10.1001/jamadermatol.2018.2526.
|
[24] |
Abdat R, Waldman RA, de Bedout V, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series[J]. J Am Acad Dermatol, 2020,83(1):46⁃52. doi: 10.1016/j.jaad.2020.01.089.
|
[25] |
Seidman JS, Eichenfield DZ, Orme CM. Dupilumab for bullous pemphigoid with intractable pruritus[J]. Dermatol Online J, 2019,25(11) :13030/qt25q9w6r9.
|
[26] |
Seyed Jafari SM, Feldmeyer L, Bossart S, et al. Case report: combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid[J]. Front Immunol, 2020,11:611549. doi: 10.3389/fimmu.2020.611549.
|
[27] |
Saleh M, Reedy M, Torok H, et al. Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature[J]. Dermatol Online J, 2021,27(4):13030/qt0dv3f9h6.
|
[28] |
Velin M, Dugourd PM, Sanchez A, et al. Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids. A monocentric real-life study[J]. J Eur Acad Dermatol Venereol, 2022. doi: 10.1111/jdv.17999.
|
[29] |
Klepper EM, Robinson HN. Dupilumab for the treatment of nivolumab⁃induced bullous pemphigoid: a case report and review of the literature[J]. Dermatol Online J, 2021,27(9). doi: 10.5070/D327955136.
|
[30] |
Zhang Y, Xu Q, Chen L, et al. Efficacy and safety of dupilumab in moderate⁃to⁃severe bullous pemphigoid[J]. Front Immunol, 2021,12:738907. doi: 10.3389/fimmu.2021.738907.
|
[31] |
杨璐, 曾跃平, 晋红中. 度普利尤单抗联合糖皮质激素治疗大疱性类天疱疮:国内首报并文献复习[J]. 中华临床免疫和变态反应杂志, 2021,15(1):47⁃52. doi: 10.3969/j.issn.1673⁃8705. 2021.01.009.
|
[32] |
潘春梅, 潘萌, 冯雨苗, 等. 度普利尤单抗治疗难治性大疱性类天疱疮1例[J]. 中国皮肤性病学杂志, 2022,36(3):311⁃314.
|